Pharmacological prevention of thromboembolism in patients with left ventricular dysfunction

American Journal of Cardiovascular Drugs

Volumn 6, Issue 1, 2006, Pages 41-49

  Thatai, Deepak ^a,b   Ahooja, Vineeta ^b   Pullicino, Patrick M ^c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

^c RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; ENALAPRIL; ENOXAPARIN; LIVER ENZYME; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; WARFARIN; XIMELAGATRAN;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ACUTE CORONARY SYNDROME; ANTICOAGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; ENZYME BLOOD LEVEL; HEART ATRIUM FIBRILLATION; HEART EJECTION FRACTION; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE FAILURE; HOSPITALIZATION; HUMAN; INCIDENCE; META ANALYSIS; MORTALITY; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SINUS RHYTHM; STROKE; SYSTEMATIC REVIEW; THROMBOEMBOLISM; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; ATRIAL FIBRILLATION; CEREBROVASCULAR ACCIDENT; HEART FAILURE, CONGESTIVE; HUMANS; INCIDENCE; PLATELET AGGREGATION INHIBITORS; RISK ASSESSMENT; STROKE VOLUME; THROMBOEMBOLISM; VENTRICULAR DYSFUNCTION, LEFT;

EID: 33644502263     PISSN: 11753277     EISSN: None     Source Type: Journal    
DOI: 10.2165/00129784-200606010-00004     Document Type: Review

References (82)

1. American Heart Association. Heart disease and stroke statistics: 2003 update. Dallas (TX): The American Heart Association, 2002
2. Massie BM, Shah NB. Evolving trends in the epidemiologic factors of heart failure: rationale for preventive strategies and comprehensive disease management. Am Heart J 1997; 133: 703-12
3. The Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing physicians' health study. N Engl J Med 1988; 318: 262-4
4. Starling RC. The heart failure pandemic: changing patterns, costs, and treatment strategies. Cleve Clin J Med 1998 Jul-Aug; 65 (7): 351-8
5. Massie BM, Krol WF, Ammon SE, et al. The Warfarin and Antiplatelet Therapy in Chronic Heart Failure Trial (WATCH): rationale, design, and baseline patient characteristics. J Card Fail 2004 Apr; 10 (2): 113-4
6. Hemura K, Pisa Z. Trends in cardiovascular disease mortality in industrialized countries since 1950. World Health Stat Q 1988; 38: 155-68
7. Kelley RE, Minagar A. Cardioembolic stroke: an update. South Med J 2003 Apr; 96 (4): 343-9
8. Kannel WB, Wolf PA, Verter J. Manifestations of coronary artery disease predisoposing to stroke: the Framingham study. JAMA 1983; 250: 2942-6
9. Roberts WC, Siegel RJ, McManus BM. Idiopathic dilated cardiomyopathy: analysis of 152 necropsy patients. Am J Cardiol 1987; 60: 1340-55
10. Cioffi G, Pozzoli M, Forni G, et al. Systematic thromboembolism in chronic heart failure: a prospective study of 406 patients. Eur Heart J 1996; 17: 1381-9
11. Katz SD, Marantz PR, Biasucci L, et al. Low incidence of stroke in patients with heart failure: a prospective study. Am Heart J 1993; 126: 141-6
12. Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. N Engl J Med 1986; 314: 1547-52
13. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991; 325: 303-10
14. Loh E, Sutton MS, Wun CC, et al. Ventricular dysfunction and risk of stroke after myocardial infarction. N Engl J Med 1997; 336: 251-7
15. The SOLVD Investigators. Effect of Enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 1325: 293-302
16. The CONSENSUS Trial Study Group. Effect of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316: 1429-35
17. Dunkman WB, Johnson GR, Carson PE, et al. Incidence of thromboembolic events in congestive heart failure: the V-HeFT Cooperative Studies Group. Circulation 1993; 87: 94-101
18. Diet F, Erdmann E. Thromboembolism in heart failure: who should be treated? Eur J Heart Fail 2000 Dec; 2 (4): 355-63
19. Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure: the PROMISE study research group. N Engl J Med 1991; 325: 1468-75
20. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: the Heart Outcomes Prevention Evaluation Study investigators. N Engl J Med 2000; 342: 145-53
21. Pullicino PM, Halperin JL, Thompson JLP. Stroke in patients with heart failure and reduced left ventricular ejection fraction. Neurology 2000; 54: 288-94
22. Sacco RL, Shi T, Zamanillo MC, et al. Predictors of mortality and recurrence after hospitalized cerebral infarction in an urban community: the Northern Manhattan Stroke Study. Neurology 1994; 44: 626-34
23. Petty GW, Brown RD, Whisnant JP, et al. Survival and recurrence after first cerebral infarction: a population-based study in Rochester, Minnesota, 1975 through 1989. Neurology 1998; 50: 208-16
24. Natterson PD, Stevenson WG, Saxon LA, et al. Risk of arterial embolization in 224 patients awaiting cardiac transplantation. Am Heart J 1995; 129: 564-70
25. Dries DL, Rosenberg Y, Waclawiw M, et al. Ejection fraction and risk of thromboembolic events in patients with systolic dysfunction and sinus rhythm: evidence of gender differences in studies of left ventricular dysfunction trials. J Am Coll Cardiol 1997; 29: 1074-80
26. Kalaria VG, Passannante MR, Shah T, et al. Effect of mitral regurgitation on left ventricular thrombus formation in dilated cardiomyopathy. Am Heart J 1998; 135 (2 Pt 1): 215-20
27. Sharma ND, McCullough PA, Philbin EF, et al. Left ventricular thrombus and subsequent thromboembolism in patients with severe systolic dysfunction. Chest 2000; 117 (2): 314-20
28. Gottdiener JS, Gay JA, Vanvoorhees L, et al. Frequency and embolic potential of left ventricular thrombus in dilated cardiomyopathy: assessment by 2-dimensional echocardiography. Am J Cardiol 1983; 52: 1281-517
29. Cabin HS, Roberts WC. Left ventricular aneurysm, intramural thrombus and systemic embolus in coronary heart disease. Chest 1980; 77: 586-90
30. Fuster V, Gersh BJ, Giuliani ER, et al. The natural history of idiopathic dilated cardiomyopathy. Am J Cardiol 1981; 47: 525-31
31. Segal JP, Stapleton JF, McClellan JR, et al. Idiopathic cardiomyopathy: clinical features, prognosis and therapy. Curr Probl Cardiol 1978; 3: 1-49
32. Meltzer RS, Visser CA, Fuster V. Intracardiac thrombi and systemic embolization. Ann Intern Med 1986 May; 104 (5): 689-98
33. Katz SD. Left ventricular thrombus and the incidence of thromboembolism in patients with congestive heart failure: can clinical factors identify patients at increased risk? J Cardiovasc Risk 1995; 2: 97-102
34. De Lorenzo F, Saba N, Kakkar VV. Blood coagulation in patients with chronic heart failure: evidence for hypercoaguable state and potential for pharmacological intervention. Drugs 2003; 63 (6): 565-76
35. Mehta J, Mehta P. Platelet function studies in heart disease: enhanced platelet aggregate formation in congestive heart failure. Circulation 1979; 60: 497-503
36. Sbarouni E, Bradshaw AF, Tuddenham E, et al. Relationship between haemostatic abnormalities and neuroendocrine activity in heart failure. Am Heart J 1994; 127 (3): 607-12
37. Bessenger E, Fink B, Skatchkov M, et al. Endothelium and platelet activity in heart failure. J Card Fail 1996; 2: 5203-8
38. Sbarouni E, Bradshaw A, Andreotti F, et al. Relationship between hemostatic abnormalities and neuroendocrine activity in heart failure. Am Heart J 1994 Mar; 127 (3): 607-12
39. Lausanne JB. European Stroke Initiative (EUSI), European Stroke Council (ESC), European Neurological Society (ENS), European Federation of Neurological Societies (EFNS). Cerebrovasc Dis 2003; 15 Suppl. 2: 1-69
40. Chamorro A. Immediate anticoagulation in acute focal brain ischemia revisited: gathering the evidence. Stroke 2001; 32: 577-8
41. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994; 154: 1449-57
42. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: stroke prevention in atrial fibrillation III randomized clinical trial. Lancet 1996; 348: 633-8
43. Ibrahim SA, Kwoh CK, Harper DL, et al. Racial differences in the utilization of oral anticoagulant therapy in heart failure: a study of elderly hospitalized patients. J Gen Intern Med 2000; 15: 134-7
44. Elwood PC, Sweetnam PM. Aspirin and secondary mortality after myocardial infarction. Lancet 1979; 2: 1313-5
45. Lewis HD, Davis JW, Archibald DG, et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina: results of a Veterans Administration Cooperative Study. N Engl J Med 1983; 309: 396-403
46. Hart RG, Pearce LA, Miller VT, et al. Cardioembolic vs noncardioembolic strokes in atrial fibrillation: frequency and effect of antithrombotic effect in the stroke prevention in atrial fibrillation studies. Cerebrovasc Dis 2000; 10: 39-43
47. Cleland JGF, Findlay I, Jafri S, et al. The Warfarin/Aspirin Study in Heart Failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure. Am Heart J 2004; 148: 157-64
48. Goldhaber SZ. The Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) Trial: a report on a presentation at the late-breaking clinical trials session of the 53rd Annual Scientific Session of the American College of Cardiology; 2004 Mar 7-10; New Orleans (LA) [online]. Available from URL:http://www.cardiologyupdate.org/crus/402-033.pdf [Accessed 2005 Jul 26]
49. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy: I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81-106
50. Cleland JG, Bulpitt CJ, Falk RH, et al. Is aspirin safe for patients with heart failure? Brit Heart J 1995; 74: 215-9
51. Aspirin Myocardial Infarction Study Research Group. A randomized, controlled trial of aspirin in persons recovering from myocardial infarction. JAMA 1980; 243: 661-8
52. Klimt CR, Knatterud GL, Stamler J, et al. Persantine-Aspirin Reinfarction Study: Part II. Secondary coronary prevention with persantine and aspirin. J Am Coll Cardiol 1986; 7: 251-69
53. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1997; 336: 251-7
54. Yusuf S, Pepine CJ, Garces C, et al. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet 1992; 340: 1173-8
55. Al-Khadra AS, Salem DN, Rand WM, et al. Antiplatelet agents and survival: a cohort analysis from the Studies Of Left Ventricular Dysfunction (SOLVD) Trial. J Am Coll Cardiol 1998; 31: 419-25
56. Harjai KJ, Nunez E, Turgut T, et al. The detrimental effect of combined aspirin and angiotensin converting enzyme inhibitor therapy on readmission rates in heart failure [abstract]. J Am Coll Cardiol 1999; 33 Suppl. A: 214A
57. Katz SD, Radin M, Graves T, et al. Effect of aspirin and ifetroban on skeletal muscle blood flow in patients with congestive heart failure treated with enalapril. J Am Coll Cardiol 1999; 34: 170-6
58. Isnard R, Baroin J-P, Drobinski G, et al. Influence of aspirin on long-term prognosis of patients with ischemic left ventricular systolic dysfunction [abstract]. Circulation 1998; 98 Suppl. I: I-300
59. Latini R, Tognoni G, Maggioni AP, et al. Clinical effects of early angiotensin-converting enzyme inhibitor treatment for acute myocardial infarction are similar in the presence and absence of aspirin: systematic overview of individual data from 96. J Am Coll Cardiol 2000; 35: 1801-7
60. Gum PA, Kottke-Merchant K, Poggio ED, et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 2001; 88: 230-5
61. Mason PJ, Jacobs AK, Freedman JE. Aspirin resistance and atherothrombotic disease. J Am Coll Cardiol 2005 Sep 20; 46 (6): 986-93
62. Sane DC, McKee SA, Malinin AI, et al. Frequency of aspirin resistance in patients with congestive heart failure treated with antecedent aspirin. Am J Cardiol 2002; 90: 893-5
63. Stroke prevention in atrial fibrillation study: final results. Circulation 1991; 84 (2): 527-39
64. Connolly SJ, Laupacis A, Gent M, et al. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol 1991; 18: 349-55
65. Secondary prevention in non-rheumatic atrial fibrillation after transient ischemic attack or minor stroke: EAFT (European Atrial Fibrillation Trial) Study Group. Lancet 1993; 342: 1255-62
66. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet 1994; 343: 687-91
67. Lip GY, Gibbs CR. Anticoagulation for heart failure in sinus rhythm: a Cochrane systematic review. QJM 2002 Jul; 95 (7): 451-9
68. Al-Khadra AS, Salem DN, Rand WM, et al. Warfarin anticoagulation and survival: a cohort analysis from the studies of left ventricular dysfunction. J Am Coll Cardiol 1998; 31: 749-53
69. Smith P, Arnesen H, Holme I. The effect of warfarin on mortality and reinfarction after myocardial infarction. N Engl J Med 1990; 323: 147-52
70. Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis (ASPECT) Research Group. Effect of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction. Lancet 1994; 343: 499-503
71. Weitz JI. Low molecular weight heparins. N Engl J Med 1997; 337: 688-98
72. De Lorenzo F, Newberry D, Scully M, et al. Low molecular weight heparin (bemiparin sodium) and the coagulation profile of patients with heart failure. Am Heart J 2002; 143: 689
73. Cohen AT, Zaw HM, Alikhan R. Benefits of deep vein thrombosis prophylaxis in non surgical patients: the MEDENOX trial. Semin Hematol 2001; 38: 31-8
74. The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345 (7): 494-502
75. Serebruany VL, Malanin AI, Jerome SD, et al. Effects of clopidogrel and aspirin combination versus aspirin alone on platelet aggregation and major receptor expression in patients with heart failure: the PLavix Use for Treatment Of Congestive Heart Failure (PLUTO-CHF) trial. Am Heart J 2003; 146 (4): 713-20
76. Francis CW, Berkowitz SD, Comp PC, et al. Comparison of ximelagatran and warfarin for the prevention of venous thromboembolism after total knee replacement. N Engl J Med 2003; 349: 1703-12
77. Halperin JL. Ximelagatran compared to warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: rationale, objectives, and design of a pair of clinical studies and baseline patient charactercitics (SPORTIF III and V). Executive Steering Committee, SPORTIF III and V study Investigators. Am Heart J 2003; 146: 431-48
78. Executive Steering Committee on behalf of SPORTIF III investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared to warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 2003; 362: 1691-8
79. Halperin JL. Efficacy and safety study of oral direct thrombin inhibitor ximelagatran comapred to with dose-adjusted warfarin on the prevention of stroke and systemic embolic events in patients with atrial fibrillation (SPORTIF V): SPORTIF V Investigators. Plenary session VII: late-breaking clinical trials. American Heart Association Scientific Session; 2003 Nov 11; Orlando (FL)
80. Olsson SB. New advances in stroke prevention in atrial fibrillation: ximelagatran and direct thrombin inhibition. Eur Heart J 2004; Suppl. 6: B20-4
81. Gurewich V. Ximelagatran: promises and concerns. JAMA 2005 Feb; 293 (6): 736-9
82. Brinker A, He R, Desai M, et al. Safety of ximelagatran. JAMA 2005 Jun; 293 (23): 2859-60